Recently Viewed
Clear All$0.02
$-0.01
(-19.54%)
As on 08-Nov-2022 09:30EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
Revenue (TTM)
$19 Mln
Net Profit (TTM)
$-32 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0
Industry P/E
24.51
EV/EBITDA
-1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
52,020,700
CFO
$-142.49 Mln
EBITDA
$-4.94 Mln
Net Profit
$-36.27 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Clarus Therapeutics Holdings (CRXT)
| -99.1 | -46.8 | -93.1 | -99.6 | -- | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate... for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. Read more
Founder, Pres, CEO & Director
Dr. Robert E. Dudley Ph.D.
Founder, Pres, CEO & Director
Dr. Robert E. Dudley Ph.D.
Headquarters
Northbrook, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Clarus Therapeutics Holdings Inc (CRXT) is $0.02 (NASDAQ) as of 08-Nov-2022 09:30 EDT. Clarus Therapeutics Holdings Inc (CRXT) has given a return of -99.59% in the last 1 years.
Since, TTM earnings of Clarus Therapeutics Holdings Inc (CRXT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2013
|
--
|
--
|
|
2012
|
--
|
--
|
The 52-week high and low of Clarus Therapeutics Holdings Inc (CRXT) are Rs -- and Rs -- as of 04-Apr-2026.
Clarus Therapeutics Holdings Inc (CRXT) has a market capitalisation of $ 2 Mln as on 08-Nov-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Clarus Therapeutics Holdings Inc (CRXT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.